| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 3,754,300 | 3,675,600 | 3,028,700 | 3,720,700 |
| Research and development | 1,475,000 | 1,421,700 | 1,327,400 | 1,271,500 |
| Acquired in-process research and development | 83,100 | 10,000 | 12,300 | 56,200 |
| Selling, general, and administrative | 657,800 | 634,200 | 633,000 | 714,400 |
| Cost of goods sold, collaboration and contract manufacturing-Product | 281,000 | 275,600 | 265,500 | 262,300 |
| Cost of goods sold, collaboration and contract manufacturing-Collaborationand Contract Manufacturing | 240,600 | 254,600 | 198,800 | 228,800 |
| Other operating (income) expense, net | 10,000 | 0 | 0 | -8,000 |
| Total expenses | 2,727,500 | 2,596,100 | 2,437,000 | 2,541,200 |
| Income from operations | 1,026,800 | 1,079,500 | 591,700 | 1,179,500 |
| Other income (expense), net | 755,800 | 442,800 | 322,000 | 327,300 |
| Interest expense | 19,300 | 3,600 | 8,700 | 13,800 |
| Total other income (expense) | 736,500 | 439,200 | 313,300 | 313,500 |
| Income before income taxes | 1,763,300 | 1,518,700 | 905,000 | 1,493,000 |
| Income tax expense | 303,300 | 127,100 | 96,300 | 152,400 |
| Net income | 1,460,000 | 1,391,600 | 808,700 | 1,340,600 |
| Unrealized gain on debt securities | 15,700 | 22,100 | 38,100 | 128,200 |
| Gain on foreign currency translation | 800 | 1,300 | -1,100 | 1,900 |
| Comprehensive income | 1,476,500 | 1,415,000 | 845,700 | 1,470,700 |
| Net income per share - basic (in dollars per share) | 14.09 | 13.24 | 7.58 | 12.4 |
| Net income per share - diluted (in dollars per share) | 13.62 | 12.81 | 7.27 | 11.54 |
| Weighted average shares outstanding - basic (in shares) | 103,600,000 | 105,100,000 | 106,700,000 | 108,100,000 |
| Weighted average shares outstanding - diluted (in shares) | 107,200,000 | 108,600,000 | 111,200,000 | 116,200,000 |
REGENERON PHARMACEUTICALS, INC. (REGN)
REGENERON PHARMACEUTICALS, INC. (REGN)